BioCryst Senior Vice President and CFO Thomas Staab tells he North Carolina Biotechnology Center that the decision means it’s business as usual for BioCryst employees after a proposed merger fell through.
Read MoreShareholders in BioCryst Pharmaceuticals rejected a merger with Pennsylvania-based Idera Pharmaceuticals in a special shareholders meeting on Tuesday.
Read MoreA large shareholder in Biocryst Pharmaceuticals argues that the drug company’s proposed merger with another drug company undervalues its assets and wants to scuttle the deal
Read More
